/NOVN

NOVN Stock - Novan, Inc.

Q: What is the analyst price target for NOVN?

Analyst price target information is not currently available for NOVN.

Q: What is NOVN's market cap?

Market capitalization information is not currently available for NOVN.

Healthcare|Biotechnology|NASDAQ

$0.09-24.84%

$0.03 (-24.84%) • Jul 25

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.10

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for NOVN

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2018

FY2019

FY2020

FY2021

FY2022

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-0.04

52W High$3.33

52W Low$0.08

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019	FY2018
Revenue	$23.61M	$2.82M	$4.21M	$4.48M	$5.99M
Gross Profit	$16.23M	$2.82M	$4.21M	$-20,695,000	$-17,054,000
Gross Margin	68.7%	100.0%	100.0%	-462.3%	-284.7%
Operating Income	$-35,390,000	$-29,915,000	$-30,214,000	$-30,688,000	$-28,561,000
Net Income	$-19,561,000	$-28,837,000	$-30,163,000	$-30,779,000	$-12,673,000
Net Margin	-82.9%	-1021.9%	-716.8%	-687.5%	-211.5%
EPS	$-0.89	$-1.69	$-3.05	$-11.72	$-4.91

Company Overview

Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Visit Website

Earnings History & Surprises

NOVN

Beat Rate

41%

Last 17 quarters

Avg Surprise

-58.4%

EPS vs Estimate

Beats / Misses

7/9

1 met exactly

Latest EPS

$-0.44

Q3 2023

EPS Surprise History

Q4 21

+19.0%

$-0.34vs$-0.42

Q1 22

-4.8%

$-0.44vs$-0.42

Q2 22

-24.6%

$-0.71vs$-0.57

Q3 22

+25.4%

$-0.44vs$-0.59

Q4 22

-10.3%

$-0.43vs$-0.39

Q1 23

-41.9%

$-0.44vs$-0.31

Q2 23

-68.8%

$-0.54vs$-0.32

Q3 23

-388.9%

$-0.44vs$-0.09

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2024	May 13, 2024	—	—	—	—
Q1 2024	Mar 28, 2024	—	—	—	—
Q4 2023	Nov 13, 2023	—	—	—	—
Q3 2023	Aug 10, 2023	$-0.09	$-0.44	-388.9%	✗ MISS
Q2 2023	May 15, 2023	$-0.32	$-0.54	-68.8%	✗ MISS
Q1 2023	Mar 15, 2023	$-0.31	$-0.44	-41.9%	✗ MISS
Q4 2022	Nov 14, 2022	$-0.39	$-0.43	-10.3%	✗ MISS
Q3 2022	Aug 11, 2022	$-0.59	$-0.44	+25.4%	✓ BEAT
Q2 2022	May 16, 2022	$-0.57	$-0.71	-24.6%	✗ MISS
Q1 2022	Feb 22, 2022	$-0.42	$-0.44	-4.8%	✗ MISS
Q4 2021	Nov 10, 2021	$-0.42	$-0.34	+19.0%	✓ BEAT
Q3 2021	Aug 12, 2021	$-0.53	$-0.39	+26.4%	✓ BEAT
Q2 2021	May 11, 2021	$-0.50	$-0.60	-20.0%	✗ MISS
Q1 2021	Feb 25, 2021	$-0.60	$-0.70	-16.7%	✗ MISS
Q4 2020	Oct 30, 2020	$-0.60	$-0.60	0.0%	= MET
Q3 2020	Aug 14, 2020	$-1.00	$-0.70	+30.0%	✓ BEAT
Q2 2020	May 20, 2020	$-0.22	$-1.70	-672.7%	✗ MISS
Q1 2020	Feb 24, 2020	$-4.50	$1.10	+124.4%	✓ BEAT
Q4 2019	Nov 12, 2019	$-4.20	$-3.20	+23.8%	✓ BEAT
Q3 2019	Aug 13, 2019	$-3.30	$-3.10	+6.1%	✓ BEAT